These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38154616)

  • 1. Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand.
    Mikamo H; Takahashi S; Yamagishi Y; Hirakawa A; Harada T; Nagashima H; Noguchi C; Masuko K; Maekawa H; Kashii T; Ohbayashi H; Hosokawa S; Maejima K; Yamato M; Manosuthi W; Paiboonpol S; Suganami H; Tanigawa R; Kawamura H;
    J Infect Chemother; 2024 Jun; 30(6):536-543. PubMed ID: 38154616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivermectin for preventing and treating COVID-19.
    Popp M; Reis S; Schießer S; Hausinger RI; Stegemann M; Metzendorf MI; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015017. PubMed ID: 35726131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial.
    Wijewickrema A; Banneheke H; Pathmeswaran A; Refai FW; Kauranaratne M; Malavige N; Jeewandara C; Ekanayake M; Samaraweera D; Thambavita D; Galappatthy P
    BMC Infect Dis; 2024 Jul; 24(1):719. PubMed ID: 39039459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Gentile N; Collins S; McCarthy MW; Jayaweera D; Castro M; Sulkowski M; McTigue K; Thicklin F; Felker GM; Ginde AA; Bramante CT; Slandzicki AJ; Gabriel A; Shah NS; Lenert LA; Dunsmore SE; Adam SJ; DeLong A; Hanna G; Remaly A; Wilder R; Wilson S; Shenkman E; Hernandez AF;
    JAMA; 2022 Oct; 328(16):1595-1603. PubMed ID: 36269852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.
    Mirahmadizadeh A; Semati A; Heiran A; Ebrahimi M; Hemmati A; Karimi M; Basir S; Zare M; Charlys da Costa A; Zeinali M; Sargolzaee M; Eilami O
    Respirology; 2022 Sep; 27(9):758-766. PubMed ID: 35738778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Manomaipiboon A; Pholtawornkulchai K; Poopipatpab S; Suraamornkul S; Maneerit J; Ruksakul W; Phumisantiphong U; Trakarnvanich T
    Trials; 2022 Aug; 23(1):714. PubMed ID: 36028897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Medina MF; Achinelli F; Guglielmone HA; Ojeda J; Farizano Salazar D; Andino G; Kawerin P; Dellamea S; Aquino AC; Flores V; Martemucci CN; Martinez SM; Segovia JE; Reynoso PI; Sosa NC; Robledo ME; Guarrochena JM; Vernengo MM; Ruiz Diaz N; Meza E; Aguirre MG
    BMC Infect Dis; 2021 Jul; 21(1):635. PubMed ID: 34215210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Early Treatment with Ivermectin among Patients with Covid-19.
    Reis G; Silva EASM; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; Campos VHS; Nogueira AMR; de Almeida APFG; Callegari ED; Neto ADF; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Rowland-Yeo K; Guyatt GH; Boulware DR; Rayner CR; Mills EJ;
    N Engl J Med; 2022 May; 386(18):1721-1731. PubMed ID: 35353979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
    López-Medina E; López P; Hurtado IC; Dávalos DM; Ramirez O; Martínez E; Díazgranados JA; Oñate JM; Chavarriaga H; Herrera S; Parra B; Libreros G; Jaramillo R; Avendaño AC; Toro DF; Torres M; Lesmes MC; Rios CA; Caicedo I
    JAMA; 2021 Apr; 325(14):1426-1435. PubMed ID: 33662102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
    Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial.
    Elshafie AH; Elsawah HK; Hammad M; Sweed EM; Seif AS; Abdel Ghaffar MM; Goda FM; Mosalam EM; Abdallah MS
    Expert Rev Anti Infect Ther; 2022 Oct; 20(10):1341-1350. PubMed ID: 35788169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.